Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Fibrinolytic agent" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fibrinolysin or agents that convert plasminogen to fibrinolysin to dissolve blood clots.
Freeze-dried fibrin matrices and methods for preparation thereof
InactiveUS20060172008A1High levelImprove distributionOrganic active ingredientsPowder deliveryFiberFreeze-drying
The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, per se or as cell-bearing implants.
Owner:PROCHON BIOTECH
Combined fibnrinolytic and antimicrobial cathether and uses thetherof
ActiveUS20100196434A1Decrease fibrinolytic activityAnti-microbial activity can be reducedBiocidePeptide/protein ingredientsMedicineFibrinolysis
Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.
Owner:TELEFLEX LIFE SCI LTD
Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
InactiveUS20060069035A1Avoid side effectsHigh activityFibrinogenPeptide/protein ingredientsStreptokinaseLANOTEPLASE
The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, or prolonging the half lives of the fibrinolytic agents by adding EEIIMD.
Owner:HIGAZI ABD AL ROOF
Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
InactiveUS6759042B2Peptide/protein ingredientsMammal material medical ingredientsCross-linkUrokinase Plasminogen Activator
The present invention relates to the cross-linked scuPA / suPAR complex and / or tcuPA / suPAR cross-linked complex, the process of preparation of the covalently bound single compound having fibrinolytic activity and use of the cross-linked scuPA / suPAR or tcuPA / suPAR complex in the prevention and / or treatment of thrombolytic disorders. The invention further relates to combination compositions and / or therapy regimens, comprising the cross-linked scuPA / suPAR complex or tcuPA / suPAR and one or more currently used plasminogen activators to achieve improved therapeutic efficacy and / or reduce side effects.
Owner:THROMBOTECH LTD (IL)
Freeze-dried fibrin matrices and methods for preparation thereof
InactiveUS7714107B2High levelImprove distributionOrganic active ingredientsPowder deliveryFiberFreeze-drying
The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, without cells or as a cell bearing implants.
Owner:PROCHON BIOTECH
Novel hydrophilic-lipophilic gel membrane and preparation method thereof
InactiveCN106821769ASpeed up skin penetrationImprove skin penetrationOrganic active ingredientsCosmetic preparationsDrug carrierWater soluble drug
The present invention relates to a novel hydrophilic-lipophilic gel membrane and a preparation method thereof; the dual hydrophilic gel is prepared from a styrene-isoprene-styrene segmented copolymer as a framework material, and also comprises oil and an organic fibrinolytic agent which have the good compatibility with the copolymer, as well as an anti-oxygen, and a hydrophilic / water-absorbing assistant. The membrane has the big characteristic of being capable of being used as a drug carrier under a condition that a surface active agent is not added, a water-soluble drug can be added, a lipophilic drug also can be added, the universality as the drug carrier is expanded, a defect that only the water-soluble drug can be added into a conventional hydrophilic gel, and only the lipophilic drug can be added into a conventional lipophilic gel is solved, each functional component can be kept in a dissolved state and can not be prone to absorb, and a dose-effect ratio relationship (have to meet) of drug components can be met; the novel hydrophilic-lipophilic gel membrane can enhance the transdermal action of the drug components to enable the drug components to fast penetrate through the skins within a short time to be absorbed.
Owner:北京乳凝创智生物技术研发中心(有限合伙)
Labelled adrenomedullin derivatives and their use for imaging and therapy
The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
Owner:PULMOSCI
Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism
InactiveUS20060222641A1Less side effectsImprove toleranceOrganic active ingredientsBiocideVeinAntioxidant
The present invention relates to a composition and method for preventing or reducing edema, deep vein thrombosis (DVT), and / or pulmonary embolism by administering a combination of a fibrinolytic agent and an antioxidant. The composition is particularly useful for treating individuals prior to or during long term flights or other situations involving extended immobility.
Owner:RIORDAN NEIL
Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
PendingUS20210001023A1Treatment and prevention and prophylaxis and amelioration and inhibitionReduced fibrinolytic activityOrganic chemistryPeptide/protein ingredientsCyclohexanecarboxylic acidCarboxylic acid
The presently disclosed subject-matter provides specific compositions, conjugates, device, kits and systems for depleting fibrinolytic agents from biological fluids. The presently disclosed subject-matter further relates to the resulting biological fluid products that are devoid in fibrinolytic activity, therapeutic methods and uses thereof. The conjugates comprise a particle, at least one linker and at least one amino acid, derivative thereof or analog thereof being at least one of 4-(aminomethyl)-cyclo-hexane-carboxylic acid (tranexamic acid), epsilon-amino caproic acid, lysine, cyclohexanecarboxylic acid and 4-methyl-cyclohexanecarboxylic acid. A plurality of different conjugates (e.g. differing in particle size or type of linker) can be used.
Owner:PLAS FREE LTD
Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
InactiveUS20030211095A1Equivalent efficacyHigh activityBiocideFibrinogenUrokinase Plasminogen ActivatorSide effect
The present invention relates to compositions of the polypeptide EEIIMI, anti-LRP antibodies, LRP antagonists, and / or one or more fibrinolytic agents comprising scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and / or prolonging the half lives of the fibrinolytic agents.
Owner:THROMBOTECH LTD (IL)
Labelled adrenomedullin derivatives and their use for imaging and therapy
The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
Owner:PULMOSCI
Labelled adrenomedullin derivatives and their use for imaging and therapy
ActiveUS8703098B2Easy to detectHigh retention rateHormone peptidesRadioactive preparation carriersMajor bleedingPULMONARY EMBOLUS
The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such us for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus.
Owner:PULMOSCI
Method for Making Biodegradable Anti-Adhesion Membranes for Cardiac Surgery
InactiveUS20160045643A1Good biocompatibilityIncreasing membrane 's elasticitySurgerySurgical drugsFiberPolymer chemistry
A method for the manufacture of biodegradable membranes for preventing adhesion formation followed open heart surgery is described herein. The manufacturing of biodegradable membranes is based on polymeric composition, comprised of copolymer of polyhydroxybutyrate / hydroxyvalerate (PHBV), poly(D,L-lactide) in the ratio of the dried powders of 3:1, the resulting mixture is dissolved in chloroform to a concentration of 6-9% followed by thorough mixing for 2 hours and heating up to 35° C. The membrane is produced by electrostatic spinning (electrospinning), wherein biologically active substances from fibrinolytic agents or direct anticoagulants are embedded in the structure of the fiber.
Owner:FEDERALNOE GOSUDARSTVENNOE BJUDZHETNOE NAUCHNOE UCHREZHDENIE NAUCHNO ISSLEDOVATELSKIJ INST KOMPLEKSNYKH PROBLEM SERDECHNO SOSUDISTYKH ZABOLEVANIJ NII KPSSZ
Fibrinolytic metalloprotease and composition comprising the same
Owner:KOREA OCEAN RES & DEV INST
Plasminogen activator mutants as anti-fibrinolytic agents
The invention relates to an anti fibrinolytic composition comprising at least one tPA mutant that carries at least one point mutation substituting Ser481 to Ala on tPA, said mutant inhibits the fibrinolytic activity of at least one of tPA and uPA and therefore may be used for treating disorders associated with fibrinolytic processes, specifically, coagulopathies, thrombocytopenia and bleeding. The invention further provides methods and uses of the mutants of the invention.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT
Treatment for airway cast obstruction
ActiveUS10415027B2Reduce obstructionImprove survivalDispersion deliveryPeptide/protein ingredientsAnesthesiaFibrin
The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent.
Owner:NAT JEWISH HEALTH
Combination therapy for the treatment and improvement of scars
InactiveUS20070265346A1Good lookingSmall sizeBiocideCosmetic preparationsClose woundsTissue remodeling
The present invention is a composition, methods of using that composition and kits including that composition, useful for reducing the size and improving the appearance of a closed wound wherein the composition comprises a therapeutically effective amount of a hydrophilic or hydrophobic carrier (or a mixture thereof), at least one matrix metalloproteinase (MMP) modulator in combination with one or more of the following pharmaceutically active agents: (a) cell cycle modulators; (b) inflammatory event modulators; (c) angiogenesis event modulators; (d) fibroblast migration agents; (e) fibroblast proliferation agents; (f) tissue remodeling correcting agents; (g) antimicrobial agents; (h)modulators of deposition of extra cellular matrix; (i) penetration enhancers; (j) antioxidants; (k) antipuritic agents; (l) fibrinolytic agents; (j) immunomodulators; (m) transcription modulating agents; (n) surface modulating agents; (o) growth factor inhibitors; and (p) anti-proliferative agents.
Owner:AVOCET POLYMER TECH
β-amyloid fibrinolytic agent, therapeutic/preventive drug for diseases caused by β-amyloid fibrosis
The present invention is to provide a β-amyloid fibrinolytic agent containing a natural product as an active ingredient, and a therapeutic drug or preventive drug for diseases caused by β-amyloid fibrosis. It is a β-amyloid fibrinolytic agent, a therapeutic drug or a preventive drug for a disease caused by β-amyloid fibrosis, containing a dry powder, ground material and / or extract of earthworms as an active ingredient. The disease caused by fibrosis of beta amyloid is preferably Alzheimer's disease.
Owner:WELL STONE
E-we thrombin analog and fibrinolytic combination
InactiveUS20200054719A1Prevent thrombosisReduces time for successful and adequate myocardial reperfusionPeptide/protein ingredientsBlood disorderDiseaseThromboembolic disorder
According to the invention, a novel combination composition and method of treatment for thrombotic disorders, e.g., STEMI in ACS patients, is disclosed. The present invention relates to thrombin analogs, e.g., WE and E-WE thrombin analogs, in combination with fibrinolytics, e.g., tPA. In particular, E-WE thrombin analog and fibrinolytic combination therapy for inhibition of thrombin mediated TAFi activation and acceleration of tPA induced thrombolysis with E-WE thrombin. The present invention also relates to methods of treating a subject having a thrombotic or thromboembolic disorder by delivering the novel composition comprised of at least one antithrombotic thrombin analog and at least one fibrinolytic agent to the subject.
Owner:ARONORA
Use of cross-linked, covalently bound urokinase plasminogen activator (scuPAR)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
InactiveUS20010046495A1Peptide/protein ingredientsMammal material medical ingredientsUrokinase Plasminogen ActivatorSide effect
The present invention relates to the cross-linked scuPA / suPAR complex and / or tcuPA / suPAR cross-linked complex, the process of preparation of the covalently bound single compound having fibrinolytic activity and use of the cross-linked scuPA / suPAR or tcuPA / suPAR complex in the prevention and / or treatment of thrombolytic disorders. The invention further relates to combination compositions and / or therapy regimens, comprising the cross-linked scuPA / suPAR complex or tcuPA / suPAR and one or more currently used plasminogen activators to achieve improved therapeutic efficacy and / or reduce side effects.
Owner:THROMBOTECH LTD (IL)
Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
PendingCN111770767AEnhanced ability to treat bleeding disordersOrganic chemistryPeptide/protein ingredientsCyclohexanecarboxylic acidCarboxylic acid
The presently disclosed subject-matter provides specific compositions, conjugates, device, kits and systems for depleting fibrinolytic agents from biological fluids. The presently disclosed subject-matter further relates to the resulting biological fluid products that are devoid in fibrinolytic activity, therapeutic methods and uses thereof. The conjugates comprise a particle, at least one linkerand at least one amino acid, derivative thereof or analog thereof being at least one of 4-(aminomethyl)-cyclo-hexane-carboxylic acid (tranexamic acid), epsilon-amino caproic acid, lysine, cyclohexanecarboxylic acid and 4-methyl-cyclohexanecarboxylic acid. A plurality of different conjugates (e.g. differing in partcile size or type of linker) can be used.
Owner:PLAS FREE LTD
Treatment for airway cast obstruction
ActiveUS20150322421A1Reduce airway obstructionImprove survivalDispersion deliveryPeptide/protein ingredientsAirway occlusionAnesthesia
The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent.
Owner:NAT JEWISH HEALTH
A kind of preparation method and application of amino acid chelated zinc modified lamina tencel fiber
ActiveCN113201801BImprove antioxidant capacityCombined fluid retentionCosmetic preparationsToilet preparationsSpinningChelated zinc
The invention discloses a preparation method and application of an amino acid chelated zinc modified Laem Tencel fiber, which is obtained through the esterification reaction of amino acid chelated zinc and Laem Tencel fiber, including ligand amino acid and zinc nitrate at a reaction temperature of 50 ℃ The chelation reaction was carried out under the conditions of ‑65℃ and pH value of 4‑7, the reaction product was precipitated by adding absolute ethanol, centrifuged and dried to obtain amino acid chelated zinc, which was dissolved in a fibrinolytic aqueous solution with cellulose pulp, Under the conditions of -130℃ and vacuum stirring, the esterification reaction was carried out for 3-4 hours to obtain the spinning solution, which was filtered and deaerated, and then wet-spun, solidified and formed in the spinning bath to obtain amino acid chelated zinc-modified ramie Tencel fiber. In the invention, the amino acid chelated zinc-modified lamina tencel fiber can improve the antioxidant property, has a good free radical scavenging effect, and can be used in the field of mask base cloth.
Owner:SHANGHAI UNIV OF ENG SCI
Method for making biodegradable anti-adhesion membranes for cardiac surgery
InactiveUS9415141B2Good biocompatibilityImprove propertiesSurgerySurgical drugsFiberPolymer chemistry
A method for the manufacture of biodegradable membranes for preventing adhesion formation followed open heart surgery is described herein. The manufacturing of biodegradable membranes is based on polymeric composition, comprised of copolymer of polyhydroxybutyrate / hydroxyvalerate (PHBV), poly (D, L-lactide) in the ratio of the dried powders of 3:1, the resulting mixture is dissolved in chloroform to a concentration of 6-9% followed by thorough mixing for 2 hours and heating up to 35° C. The membrane is produced by electrostatic spinning (electrospinning), wherein biologically active substances from fibrinolytic agents or direct anticoagulants are embedded in the structure of the fiber.
Owner:FEDERALNOE GOSUDARSTVENNOE BJUDZHETNOE NAUCHNOE UCHREZHDENIE NAUCHNO ISSLEDOVATELSKIJ INST KOMPLEKSNYKH PROBLEM SERDECHNO SOSUDISTYKH ZABOLEVANIJ NII KPSSZ
Serine protease isolated from the venom of bombus ignitus as fibrinogenolytic and fibrinolytic enzymes
InactiveCN102146364BAnthropod material medical ingredientsPeptide/protein ingredientsFibrinogenSerine protease
Disclosed is serine protease isolated from Bombus ignitus, a bumble bee, capable of activating prothrombins and degrading fibrinogens and fibrins. Since the serine protease of the present invention enables to activate the prothrombin and directly degrade fibrinogens and fibrins it can be used in the development of a therapeutic agent for the treatment of thrombosis.
Owner:陈炳来
Fibrionolytic metalloprotease and composition comprising the same
InactiveUS20090317890A1Increase fibrinolytic activityBacteriaSugar derivativesProteinase activityNucleotide
The present invention relates to a novel protease, a polynucleotide encoding the protease, and a fibrinolytic agent comprising the same. The protease is obtained from a new gene source by using metagenomic library technology, and can replace the conventional fibrinolytic agent.
Owner:KOREA OCEAN RES & DEV INST
Labelled Adrenomedullin Derivatives and Their Use for Imaging and Therapy
ActiveUS20080274050A1Efficient implementationStrong specificityHormone peptidesBiocideMajor bleedingPULMONARY EMBOLUS
The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such us for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus.
Owner:PULMOSCI
Combined fibrinolytic and antimicrobial catheter and uses thereof
Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.
Owner:TELEFLEX LIFE SCI LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com